



भाकृअनुप-केन्द्रीय पक्षी अनुसंधान संस्थान  
इज्जतनगर, बरेली - 243 122 (उ०प्र०)  
ICAR-CENTRAL AVIAN RESEARCH INSTITUTE  
Izatnagar, Bareilly - 243 122 (U.P.)  
(AN ISO 9001:2008 CERTIFIED INSTITUTION)



पत्रांक सं०/F.No.CARI/Misc./COVID-19/2019-20

दिनांक/Date: 25.03.2021

पृष्ठांकन

सचिव, भारत सरकार, स्वास्थ्य एवं परिवार कल्याण विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय के पत्र संख्या DO No. 2061200/2021/Immunization दिनांक 22 मार्च, 2021 की प्रति आवश्यक कार्यवाही एवं अनुपालन हेतु अग्रेषित की जाती है।

संलग्न: उपरोक्तानुसार

(गोपाल दत्त मैनाली)  
सहायक प्रशासनिक अधिकारी

वितरण:

1. समस्त प्रभारी प्रभागाध्यक्षों/अनुभागाध्यक्षों/अनुभाग अधिकारियों के०प०अ०सं०, इज्जतनगर, को इस आशय से प्रेषित है कि वे उपरोक्त संलग्न पत्र की सूचना से अपने अधीनस्थ वैज्ञानिकों, अधिकारियों एवं कर्मचारियों को अवगत करायें।
2. निदेशक के निजी सचिव, के०प०अ०सं०, इज्जतनगर।
3. प्रभारी ए०के०एम०यू०, को इस आशय के साथ प्रेषित है कि कृपया इस पृष्ठांकन के साथ संलग्न पत्र को संस्थान की वेबसाइट पर अपलोड करने का कष्ट करें।
4. सुरक्षित पत्रावली।



भारत सरकार  
स्वास्थ्य एवं परिवार कल्याण विभाग  
स्वास्थ्य एवं परिवार कल्याण मंत्रालय

Government of India  
Department of Health and Family Welfare  
Ministry of Health and Family Welfare

DO No. 2061200/2021/Immunization  
22<sup>nd</sup> March 2021

राजेश भूषण, आईएएस  
सचिव

RAJESH BHUSHAN, IAS  
SECRETARY

COVID-19 vaccination drive in India has completed 65 days during which we have been able to vaccinate 3.75 crore beneficiaries of which 75 lakh beneficiaries have completed the two dose schedule of vaccination 4-6 weeks apart as per the recommendation of NEGVAC.

2. In view of the emerging scientific evidence, the interval between two doses of a specific COVID-19 vaccine i.e. COVISHIELD, has been revisited by National Technical Advisory Group on Immunization (NTAGI) and subsequently by NEGVAC in its 20<sup>th</sup> meeting during which the recommendation has been revised to provide 2<sup>nd</sup> dose of COVISHIELD at 4-8 weeks' interval after 1<sup>st</sup> dose instead of earlier practiced interval of 4-6 weeks.

3. MoHFW, Government of India has since accepted the recommendations of NTAGI and NEGVAC. Therefore, the States & UTs are advised to ensure 2<sup>nd</sup> dose of COVISHIELD to beneficiaries within this stipulated time interval of 4-8 weeks after 1<sup>st</sup> dose. Keeping the existing scientific evidence in view, it appears that protection is enhanced if the second dose of COVISHIELD is administered between 6-8 weeks, but not later than stipulated period of 8 weeks.

4. I request you to kindly instruct the concerned officials to undertake necessary steps to widely disseminate the message of revised dosing interval amongst programme managers, vaccinators and recipients of COVISHIELD vaccine and ensure adherence of revised dosing interval. Please take note that this decision of revised time interval between two doses is applicable only to COVISHIELD and NOT to COVAXIN Vaccine.

AAO  
23-03-2021

ms Adhikari do the needful  
hsh

Yours sincerely

(Rajesh Bhushan)

Chief Secretary, All States & UTs

✓ Copy to: Additional Chief Secretary / Principal Secretary / Secretary (Health)  
All States & UTs

(Rajesh Bhushan)



अभिलेख अनुभाग/Record Section  
डाइरी नं./Diary No. 1127

AAO  
Circulate Pl.  
25/03/21